Abstract
OBJECTIVE: This updated meta-analysis determines the effect of dipeptidyl peptidase-4 inhibitors on glycemic and tolerability outcomes in patients with type 2 diabetes mellitus and chronic kidney disease with glomerular filtration rate of ⩽60 mL/min or on dialysis.
METHODS: In all, 14 citations were identified from multiple databases. Qualitative assessments and quantitative analyses were performed.
RESULTS: There were 2261 participants, 49-79 years of age, 49% men and 44% Caucasians. In seven placebo-comparator studies, reduction in hemoglobin A1c at weeks 12-24 was 0.55% (95% confidence interval: -0.68 to -0.43), P
CONCLUSIONS: Dipeptidyl peptidase-4 inhibitors in patients with chronic kidney disease caused a modest reduction in hemoglobin A1c versus placebo, but not when compared with sulfonylureas or albiglutide, or when used in patients on dialysis. Additional active-comparator studies are needed to further elucidate the role of dipeptidyl peptidase-4 inhibitors in patients with chronic kidney disease stages 3-5 or on dialysis.
| Original language | American English |
|---|---|
| Pages (from-to) | 2050312116659090 |
| Journal | SAGE Open Medicine |
| Volume | 4 |
| DOIs | |
| State | Published - Jan 1 2016 |
Bibliographical note
Publisher Copyright:© The Author(s) 2016.
ASJC Scopus Subject Areas
- General Medicine
Keywords
- chronic kidney disease
- dialysis
- dipeptidyl peptidase-4 inhibitors
- linagliptin
- meta-analysis
- saxagliptin
- sitagliptin
- type 2 diabetes mellitus
- vildagliptin
- Sitagliptin
- Chronic kidney disease
- Type 2 diabetes mellitus
- Meta-analysis
- Dipeptidyl peptidase-4 inhibitors
- Dialysis
- Linagliptin
- Vildagliptin
- Saxagliptin
Disciplines
- Medicine and Health Sciences
- Pharmacy and Pharmaceutical Sciences